Cancer pathogenesis and therapy最新文献

{"title":"Cover","authors":"","doi":"10.1016/S2949-7132(24)00090-9","DOIUrl":"10.1016/S2949-7132(24)00090-9","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 1","pages":"Page OFC"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143094499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal methylated syndecan-2 (SDC2) testing for early screening of colorectal cancerous and precancerous lesions: A real-world retrospective study in China","authors":"Boyu Qin ,&nbsp;Haitao Niu ,&nbsp;Lupeng Qiu ,&nbsp;Hongfeng Zhou ,&nbsp;Peng Lyu","doi":"10.1016/j.cpt.2024.02.002","DOIUrl":"10.1016/j.cpt.2024.02.002","url":null,"abstract":"<div><h3>Background</h3><div>Colorectal cancer (CRC) is a major public health concern and the second leading cause of cancer-related deaths worldwide. However, challenges remain in deploying effective screening strategies for early-stage CRC. This study aimed to evaluate the effectiveness of a fecal-based syndecan-2 (<em>SDC2</em>) methylation test for the detection of colorectal lesions and CRC.</div></div><div><h3>Methods</h3><div>We retrospectively collected data on participants who underwent fecal <em>SDC2</em> methylation testing from January 1, 2019, to May 30, 2023. Patients with positive results were recommended to undergo colonoscopy. Performance indicators associated with certain clinical characteristics, including positive rate (PR), positive predictive value (PPV), and colonoscopy compliance rate (CCR), were subjected to statistical analysis.</div></div><div><h3>Results</h3><div>We analyzed data from 113,209 participants, of whom 11,841 (10.4% PR) had positive fecal <em>SDC2</em> methylation test results. A total of 4315 participants with positive results adhered to the colonoscopy recommendations, and the CCR was 36.4%. Finally, 3169 colorectal lesions were detected, including 1134 polyps, 875 non-advanced adenomas (NAAs), 770 advanced adenomas (AAs), and 390 CRCs, with PPV values of 26.3% (1134/4315), 20.3% (875/4315), 17.8% (770/4315), and 9.0% (390/4315), respectively. Notably, the PPV for CRC increased significantly with age (<em>χ</em>² = 164.40, <em>P</em> &lt; 0.0001). In addition, as the cycle threshold (CT) values increased, the PPVs of AAs and CRCs generally decreased, whereas those of NAAs and polyps significantly increased. Moreover, the clinical patient group had the highest incidence of late-stage CRC (stage II and higher), whereas asymptomatic populations from the staff physical examination group and rural town-based screening programs had the highest number of stage 0 and I CRCs detected (<em>P</em> = 0.0107).</div></div><div><h3>Conclusions</h3><div>This study indicates that fecal <em>SDC2</em> methylation testing combined with colonoscopy may be an effective screening method for colorectal lesions and CRC.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 1","pages":"Pages 60-67"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140467413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Despicable role of epithelial–mesenchymal transition in breast cancer metastasis: Exhibiting de novo restorative regimens","authors":"Paras Famta ,&nbsp;Saurabh Shah ,&nbsp;Biswajit Dey ,&nbsp;Kondasingh Charan Kumar ,&nbsp;Deepkumar Bagasariya ,&nbsp;Ganesh Vambhurkar ,&nbsp;Giriraj Pandey ,&nbsp;Anamika Sharma ,&nbsp;Dadi A. Srinivasarao ,&nbsp;Rahul Kumar ,&nbsp;Santosh Kumar Guru ,&nbsp;Rajeev Singh Raghuvanshi ,&nbsp;Saurabh Srivastava","doi":"10.1016/j.cpt.2024.01.001","DOIUrl":"10.1016/j.cpt.2024.01.001","url":null,"abstract":"<div><div>Breast cancer (BC) is the most prevalent cancer in women globally. Anti-cancer advancements have enabled the killing of BC cells through various therapies; however, cancer relapse is still a major limitation and decreases patient survival and quality of life. Epithelial-to-mesenchymal transition (EMT) is responsible for tumor relapse in several cancers. This highly regulated event causes phenotypic, genetic, and epigenetic changes in the tumor microenvironment (TME). This review summarizes the recent advancements regarding EMT using de-differentiation and partial EMT theories. We extensively review the mechanistic pathways, TME components, and various anti-cancer adjuvant and neo-adjuvant therapies responsible for triggering EMT in BC tumors. Information regarding essential clinical studies and trials is also discussed. Furthermore, we also highlight the recent strategies targeting various EMT pathways. This review provides a holistic picture of BC biology, molecular pathways, and recent advances in therapeutic strategies.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 1","pages":"Pages 30-47"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer phylogenetic inference using copy number alterations detected from DNA sequencing data","authors":"Bingxin Lu","doi":"10.1016/j.cpt.2024.04.003","DOIUrl":"10.1016/j.cpt.2024.04.003","url":null,"abstract":"<div><div>Cancer is an evolutionary process involving the accumulation of diverse somatic mutations and clonal evolution over time. Phylogenetic inference from samples obtained from an individual patient offers a powerful approach to unraveling the intricate evolutionary history of cancer and provides insights that can inform cancer treatment. Somatic copy number alterations (CNAs) are important in cancer evolution and are often used as markers, alone or with other somatic mutations, for phylogenetic inferences, particularly in low-coverage DNA sequencing data. Many phylogenetic inference methods using CNAs detected from bulk or single-cell DNA sequencing data have been developed over the years. However, there have been no systematic reviews on these methods. To summarize the state-of-the-art of the field and inform future development, this review presents a comprehensive survey on the major challenges in inference, different types of methods, and applications of these methods. The challenges are discussed from the aspects of input data, models of evolution, and inference algorithms. The different methods are grouped according to the markers used for inference and the types of the reconstructed trees. The applications include using phylogenetic inference to understand intra-tumor heterogeneity, metastasis, treatment resistance, and early cancer development. This review also sheds light on future directions of cancer phylogenetic inference using CNAs, including the improvement of scalability, the utilization of new types of data, and the development of more realistic models of evolution.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"3 1","pages":"Pages 16-29"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover","authors":"","doi":"10.1016/S2949-7132(24)00061-2","DOIUrl":"10.1016/S2949-7132(24)00061-2","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 4","pages":"Page OFC"},"PeriodicalIF":0.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000612/pdfft?md5=270c2ec1a7469c6d82835f103e4ad7c8&pid=1-s2.0-S2949713224000612-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology” [Cancer Pathog Ther. 2024;2:205–211]","authors":"Yutong Wang,&nbsp;Mengzhen Wang,&nbsp;Bin Chu,&nbsp;Minqiu Lu,&nbsp;Lei Shi,&nbsp;Shan Gao,&nbsp;Yuan Chen,&nbsp;Qin Yan,&nbsp;Na Ji,&nbsp;Li Bao","doi":"10.1016/j.cpt.2024.09.002","DOIUrl":"10.1016/j.cpt.2024.09.002","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 4","pages":"Page 322"},"PeriodicalIF":0.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000740/pdfft?md5=8197f488f675a9997adb43276a86d3db&pid=1-s2.0-S2949713224000740-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of myeloproliferative neoplasms with multiple myeloma","authors":"Qiuqing Xiang,&nbsp;Bin Chu,&nbsp;Minqiu Lu,&nbsp;Lei Shi,&nbsp;Yutong Wang,&nbsp;Lijuan Fang,&nbsp;Yuan Chen,&nbsp;Kai Sun,&nbsp;Li Bao","doi":"10.1016/j.cpt.2023.12.001","DOIUrl":"10.1016/j.cpt.2023.12.001","url":null,"abstract":"","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 212-214"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223001040/pdfft?md5=cf28a36367134c52d974f79284d0bfa9&pid=1-s2.0-S2949713223001040-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138611327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of choroid plexus papilloma: Current perspectives and future directions","authors":"Esma'il Akade ,&nbsp;Fereshteh Aslani ,&nbsp;Kimia Verdi ,&nbsp;Mohammad Bahadoram ,&nbsp;Gholam Abbas Kaydani","doi":"10.1016/j.cpt.2023.09.005","DOIUrl":"10.1016/j.cpt.2023.09.005","url":null,"abstract":"<div><p>Choroid plexus papilloma (CPP) is a rare, slow-growing, and typically benign brain tumor that predominantly affects children. CPP is characterized by well-defined circular or lobulated masses in the ventricles, leading to symptoms related to increased intracranial pressure and hydrocephalus. CPP diagnosis relies on a combination of clinical presentation, imaging findings, and histological examination. The World Health Organization (WHO) classification categorizes choroid plexus tumors into CPP (Grade І), atypical CPP (aCPP, Grade II), and choroid plexus carcinoma (CPC, Grade III). This article reviewed current diagnostics modalities and explored the emergence of new diagnostic methods for CPP. Research on molecular markers and genetic alterations associated with CPP is ongoing, and some potential markers have been identified. These results offered insights into potential therapeutic targets and personalized treatment approaches for CPP. Advancements in radiomics and liquid biopsy hold promise for improving diagnostic accuracy and monitoring treatment outcomes for choroid plexus tumors. Radiomics can provide quantitative data from imaging studies, whereas liquid biopsy can analyze tumor-derived genetic material and molecular markers from body fluids, such as cerebrospinal fluid (CSF) and blood. The rapidly evolving fields of molecular and genetic research and novel diagnostic methods require continuous updates and advancements before their application in clinical practice. We hope that these advancements will lead to earlier and more precise diagnoses, better treatment options, and improved outcomes in patients with CPP and other brain tumors.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 173-179"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000551/pdfft?md5=bb17f6201eedfa788f475b6b3dbcdd46&pid=1-s2.0-S2949713223000551-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134961973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overall survival associated with surgery, radiotherapy, and chemotherapy in metastatic vulvar cancer: A retrospective cohort study based on the SEER database","authors":"Xiaolin Meng ,&nbsp;Shuaiqingying Guo ,&nbsp;Xue Feng ,&nbsp;Jihui Ai ,&nbsp;Jie Yang","doi":"10.1016/j.cpt.2023.08.003","DOIUrl":"10.1016/j.cpt.2023.08.003","url":null,"abstract":"<div><h3>Background</h3><p>Large cancer registries help analyze the prognosis of rare malignancies, such as advanced vulvar cancer. This study aimed to compare the overall survival (OS) rates of patients with metastatic vulvar cancer who had undergone chemoradiotherapy and radiotherapy alone and identify prognostic factors using data from the Surveillance, Epidemiology, and End Results (SEER) registry.</p></div><div><h3>Methods</h3><p>In this retrospective cohort study, we used the SEER database to identify patients with metastatic vulvar cancer diagnosed between 2000 and 2019. Propensity score matching was performed to balance the covariates. Kaplan–Meier curves and Cox models were used to analyze OS.</p></div><div><h3>Results</h3><p>A total of 685 patients were included and divided into chemoradiotherapy and radiotherapy groups, and 400 patients were included after propensity score matching. The chemoradiotherapy group had higher OS in the matched cohort (hazard ratio [HR] = 0.7367; 95% confidence interval [CI]: 0.5906–0.9190; <em>P</em> = 0.0049) than the radiotherapy group, which was similar to that in the pre-matched cohort (<em>P</em> &lt; 0.0001). Patients who had undergone surgery + radiotherapy with or without chemotherapy showed higher OS rates than those who had received radiotherapy with or without chemotherapy for patients aged &lt;75 years and local tumor excision/destruction or surgical removal of the primary site was the recommended surgical choice (<em>P</em> &lt; 0.05). Chemoradiotherapy is sufficient for patients ≥75 years of age.</p></div><div><h3>Conclusions</h3><p>Patients with metastatic vulvar cancer should undergo surgery if they can tolerate it. Adjuvant chemoradiotherapy should be encouraged because this treatment modality was associated with higher OS than radiotherapy alone.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 195-204"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000502/pdfft?md5=ba5d57911f6f16cb4429e235c04b3aa5&pid=1-s2.0-S2949713223000502-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78276324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of PD-1/PD-L1 inhibitors on survival in stage III non-small-cell lung cancer: A systematic review","authors":"Petros Roussos,&nbsp;Magdalini Migkou","doi":"10.1016/j.cpt.2023.09.004","DOIUrl":"10.1016/j.cpt.2023.09.004","url":null,"abstract":"<div><h3>Background</h3><p>Lung cancer is the leading cause of cancer-related death, and non-small-cell lung cancer (NSCLC) is the predominant subtype. Programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors are widely used to treat stage IV NSCLC. This study systematically reviewed the literature to clarify the impact of PD-1/PD-L1 inhibitor treatment on the survival of patients with stage III NSCLC.</p></div><div><h3>Methods</h3><p>Randomized phase III clinical trials of PD-1/PD-L1 inhibitors administered to patients with stage III NSCLC that were written in English and published between November 2012 and November 2022 were eligible for review. The sources of information were the MEDLINE database (last consulted on December 26, 2022), ScienceDirect website (last consulted on December 26, 2022), and CENTRAL register (last consulted on December 27, 2022). The outcomes of interest were overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), and event-free survival (EFS). Risk of bias assessments were performed according to the Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. The findings have been assessed for certainty according to the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) guidelines.</p></div><div><h3>Results</h3><p>Fourteen eligible studies and 2788 participants were included in the review. The key characteristics used to group the participants were disease histology, percentage of PD-L1 expression in cancer cells, and timeline of therapy. OS and PFS were improved (risk ratio [RR]: 0.85; 95% confidence interval [CI]: 0.75–0.96 and RR: 0.75; 95% CI: 0.70–0.86, respectively) based on the use of PD-L1 inhibitors after chemoradiation and OS was improved using first-line PD-1 inhibitors plus chemotherapy in non-squamous NSCLC (RR: 0.40; 95% CI: 0.17–0.95), with the GRADE results indicating moderate quality of evidence.</p></div><div><h3>Conclusion</h3><p>This review highlights the OS and PFS benefits of PD-L1 inhibitors in stage III NSCLC when used after chemoradiation and OS benefits of first-line PD-1 inhibitors added to chemotherapy in non-squamous stage III disease.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 3","pages":"Pages 155-163"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S294971322300054X/pdfft?md5=4c555b7c74c1e9642328e6b71e324039&pid=1-s2.0-S294971322300054X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135389593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}